News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitget UEX Daily | Trump Ends Government Shutdown; Software Stocks Hit by AI Tools; Nvidia Plans Massive Investment in OpenAI (February 4, 2026)2BitMine adds 41,000 ETH to its balance sheet, while its unrealized losses amount to $6B3XRP price prediction: What the loss of the $1.77 swing low means for you
Wosh wants to reduce idle funds? First, overcome the interest rate hurdle
丹湖渔翁·2026/02/04 07:35
Glaxo: Fourth Quarter Earnings Overview
101 finance·2026/02/04 07:27
Samsung Electronics' Market Value Surpasses 1,000 Trillion KRW for the First Time
新浪财经·2026/02/04 06:56
TomTom sees lower to steady revenue in 2026, followed by growth in 2027
101 finance·2026/02/04 06:45
Avalanche adoption is exploding – but AVAX now faces its biggest test
AMBCrypto·2026/02/04 06:33
Anthropic's new AI tools deepen selloff in data analytics and software stocks, investors say
101 finance·2026/02/04 05:51
VeChain (VET) Price Prediction 2026, 2027 – 2030: Long-Term Forecast and Market Outlook
Coinpedia·2026/02/04 05:30
Trump administration intensifies actions to secure vital mineral resources from sources beyond China
101 finance·2026/02/04 05:12
Are We in a Bear Market for Bitcoin? Anthony Pompliano Responds
BitcoinSistemi·2026/02/04 05:03
Flash
07:34
Spot silver returns above $90 spot silver is accelerating its rise, climbing back above the $90/ounce mark, up more than 5% intraday, rebounding over $18 from this week's low.
07:29
Spot silver returns above $90PANews, February 4th – According to Golden Ten Data, spot silver accelerated its rise, climbing back above the $90/ounce mark, up more than 5% on the day and rebounding over $18 from this week's low.
07:18
GSK Q4 earnings beat expectations, driven by strong performance of HIV and asthma drugsGlonghui, February 4th｜British pharmaceutical giant GlaxoSmithKline released its financial report on Wednesday, showing that thanks to the strong performance of its HIV and asthma drugs, the company's fourth-quarter profits exceeded expectations. The UK-based pharmaceutical company stated that adjusted earnings per share, excluding certain items, were 25.5 pence, higher than analysts' expectations. The company expects profit growth this year to be between 7% and 9%. Previously, some analysts had forecast earnings per share growth guidance of around 6% to 8%. Newly appointed CEO Luke Miels has set a highly ambitious target that is likely to be surpassed, and sales of the cancer drug Blenrep are also expected to boost revenue this year.
News